KFDA to approve Tracleer, a PAH therapy.

Actelion Pharmaceuticals Korea said that the KFDA approved Tracleer 62.5mg tab.(active substance: bosentan) for the treatment of pulmonary arterial hypertension (PAH).

Tracleer is an oral endothelin receptor antagonist (ERA), which was developed as the first ERA drug in the world, showing a strong antagonistic activity against the endothelin A and B receptors. Endothelin was known as a stro...